相关实验视频
Updated: May 6, 2026

07:40
Multi-Modal Home Sleep Monitoring in Older Adults
Published on: January 26, 2019
7.6K
患有肝脏糖原储存疾病的儿童的睡眠质量,一个前性观察试点研究
Lucas Agnoletto1,2, Moya Vandeleur1,3, Mary White1,4,5
1Murdoch Children's Research Institute Melbourne Victoria Australia.
JIMD reports
|December 26, 2024
概括
患有肝脏糖原储存疾病 (GSD) 的儿童睡眠质量差,生活质量降低 (QoL). 晚间养策略,特别是玻尿酸养,可能会对睡眠产生负面影响,而不是葡萄糖水平.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 睡眠医学 睡眠医学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 肝脏糖原储存疾病 (GSDs) 涉及肝脏糖原代谢中的酶缺陷.
- 碳水化合物补充剂是常见的,以预防肝脏GSDs的夜间低血糖症.
- 新出现的证据表明,夜间失糖症可能会影响肝脏GSD儿童的睡眠质量.
研究的目的:
- 报告肝 GSD 的儿童的睡眠质量和持续时间.
- 研究夜间血糖概况,饮食管理和睡眠结果之间的关系.
- 在这个儿科队列中评估生活质量 (QoL).
主要方法:
- 长达7天的前性观察性研究,对7名患有肝脏GSD的儿童 (1-17岁) 进行了观察.
- 利用行为摄影,睡眠日记和客观和主观睡眠评估问卷.
- 使用持续血糖监测 (CGM) 和记录的饮食管理策略监测夜间血糖概况.
主要成果:
- 客观和主观睡眠质量很差;没有孩子达到建议的睡眠时间.
- 报告说,有大量的白天嗜睡和不良的睡眠卫生.
- 与其他策略相比,夜间玻尿酸养 (OBF) 的儿童的睡眠时间较短; QoL结果很差.
结论:
- 患有肝脏GSD的儿童通常会经历睡眠障碍和降低QOL.
- 一夜间的营养干预,特别是OBF,可能比葡萄糖水平更有害于睡眠.
- 未来的管理策略应该考虑一夜间食对睡眠和质量生活的影响.
相关概念视频
Inborn Errors of Metabolism
1.1K
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
1.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Hepatic Encephalopathy
53
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
53

